Withdrawal Of Two Leading Plaintiff Experts Changed The Negotiating Power Behind The 2026 Talc Settlement
The loss of important expert testimony increased litigation uncertainty and helped create new pressure for resolving thousands of ovarian cancer claims
Wednesday, August 5, 2026 - The withdrawal of two important plaintiffs' experts changed the balance of the federal talc litigation shortly before the proposed $5.5 billion settlement was announced. Expert witnesses are central to product-liability cases because plaintiffs must present qualified scientific and medical testimony connecting an alleged exposure to a particular disease. In the federal talc proceedings, plaintiffs had relied on experts to explain both general causation and specific causation. General causation concerns whether repeated genital talc use is capable of contributing to ovarian cancer. Specific causation concerns whether talc contributed to one particular claimant's diagnosis. Women diagnosed with ovarian cancer after prolonged powder use may qualify to pursue a talcum powder ovarian cancer claim and may wish to review their evidence with a baby powder cancer attorney. When plaintiffs withdrew experts involved in supporting individual causation opinions, the defense gained a stronger argument that many claims lacked the medical evidence required to reach juries. The withdrawals did not automatically dismiss thousands of lawsuits, but they increased the possibility that the court could require new reports, replacement experts, or more detailed medical proof from individual claimants.
The timing of the withdrawals was especially important because six federal bellwether cases were being prepared as test trials for the larger docket. Bellwether trials are intended to show how representative claims may perform before juries and to help the parties estimate possible settlement values. If the plaintiffs' causation experts could not continue supporting those cases, the planned trials faced delay or possible dismissal. The federal court later questioned whether nearly 69,000 claimants possessed admissible expert evidence connecting talc use to their individual cancers. Plaintiffs were given until November 2026 to explain why their claims should survive. That development created new leverage for the defense. Before the expert problem emerged, plaintiffs could point to the possibility of multiple jury trials and potentially large verdicts. Afterward, the defense could argue that thousands of cases might never reach trial because their medical proof was incomplete. Plaintiffs still had significant negotiating power, including previous verdicts, extensive product evidence, and the cost of defending tens of thousands of cases. However, the risk of widespread dismissals made a guaranteed settlement payment more attractive than it might have appeared when the bellwether program seemed secure.
The expert withdrawals also help explain why plaintiffs' firms may support a settlement valued below earlier bankruptcy proposals. A previous resolution plan had been valued at roughly $9 billion to $10 billion, while the new voluntary agreement begins at approximately $5.5 billion. The difference does not necessarily mean that the underlying injuries became less serious. It reflects the changing legal risks facing both sides. Plaintiffs must now consider whether they can locate replacement experts, revise thousands of medical evaluations, and satisfy stricter demands for claimant-specific causation evidence. Continuing the litigation could produce large awards in strong cases, but it could also lead to dismissals before juries hear the claims. The proposed settlement offers a more predictable route, with substantial payments expected to begin in 2027, although at least 95 percent of eligible claimants must participate.
OnderLaw, LLC -